Pomerantz Law Firm Investigates Potential Securities Fraud Allegations Against Outset Medical, Inc.

Investor Alert: Outset Medical Under Investigation

Pomerantz LLP, a prominent law firm based in New York, is currently investigating claims regarding Outset Medical, Inc. (NASDAQ: OM), aimed at protecting the interests of investors affected by recent financial disclosures. Investors who believe they may have suffered losses are encouraged to reach out for further information and potential participation in a class action route.

The investigation stems from the company's announcement on November 10, 2025, where they reported their third-quarter financial results. The results revealed a non-GAAP earnings per share of -$0.69, which missed analysts' average estimates by $0.03. Furthermore, their revenue of $29.43 million failed to meet expectations, falling short by $1.27 million. An announcement regarding a revised revenue outlook for the full year 2025 further frustrated investors, as it was lowered from a previously anticipated range of $122 million - $126 million to $115 million - $120 million. The company cited delays in closing significant business opportunities that were expected in the latter half of the fiscal year.

The immediate impact of these financial revelations was significant, with Outset Medical's stock price plummeting by 48.47%, equating to a downturn of $5.85 per share, closing at $6.22 on November 11. This drastic decline has prompted the legal team's inquiry into whether the company's actions potentially constitute securities fraud or other unlawful business activities.

Pomerantz LLP is recognized as a leader in the area of corporate, securities, and antitrust class litigation. Established by Abraham L. Pomerantz over 85 years ago, the firm has a longstanding tradition of fighting for the rights of investors. Their experience in class action litigation has seen them recover substantial damages for class members in instances of corporate malpractice and breaches of fiduciary duty.

With offices across major cities worldwide, including Chicago, Los Angeles, London, and Tel Aviv, Pomerantz continues its mission to hold corporations accountable for their actions. Investors in Outset Medical who suspect they have been affected by these developments are encouraged to contact attorney Danielle Peyton at Pomerantz. Further details on joining the class action are available via their outreach channels.

This situation serves as a reminder of the broader responsibilities that companies have toward their shareholders and the repercussions when expectations are not met.

For those who wish to reach out for assistance, Danielle Peyton can be contacted at [email protected] or through the direct line at 646-581-9980, ext. 7980.

Stay informed about this unfolding situation as the investigation progresses, and remember that the legal remedies available can provide necessary assistance for investors facing unforeseen challenges.